The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma.
Michael B. Atkins
Expert Testimony - CureTech
Ragini Reiney Kudchadkar
No relevant relationships to disclose
Mario Sznol
No relevant relationships to disclose
David F. McDermott
Expert Testimony - CureTech
Michal Lotem
No relevant relationships to disclose
Jacob Schachter
Expert Testimony - CureTech
Jedd D. Wolchok
No relevant relationships to disclose
Walter John Urba
No relevant relationships to disclose
Timothy Kuzel
No relevant relationships to disclose
Lynn Mara Schuchter
No relevant relationships to disclose
Craig L. Slingluff
No relevant relationships to disclose
Marc S. Ernstoff
No relevant relationships to disclose
Joseph W. Fay
No relevant relationships to disclose
Philip Adam Friedlander
No relevant relationships to disclose
Thomas Gajewski
No relevant relationships to disclose
Hassane M. Zarour
No relevant relationships to disclose
Rinat Rotem-Yehudar
Employment or Leadership Position - CureTech
Jeffrey Alan Sosman
No relevant relationships to disclose